FKBP51 regulates decidualization through Ser473 dephosphorylation of AKT

Muyun Wei1, Ying Gao1, Bingru Lu1, Yulian Jiao1, Xiaowen Liu1, Bin Cui1, Shengnan Hu1, Linying Sun1, Shaowei Mao1, Jing Dong1, Lei Yan2, Zijiang Chen2 and Yueran Zhao1,2

1Department of Centre Laboratory, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China and 2Centre for Reproductive Medicine, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China

Correspondence should be addressed to Y Zhao; Email: yanzhao@163.com

Abstract

Defective decidualization of human endometrial stromal cells (ESCs) has recently been highlighted as an underlying cause of implantation failure. FK-506-binding protein 51 (FKBP51) has been shown to participate in the steroid hormone response and the protein kinase B (AKT) regulation process, both of which are important pathways involved in decidualization. The objective of the present study was to investigate the potential effects and mechanisms of FKBP51 in the regulation of ESC decidualization. By performing immunohistochemical staining on an endometrial tissue microarray (TMA) derived from normal females, we found that FKBP51 expression was much higher in the luteal phase than in the follicular phase in ESCs. Primary ESCs were isolated from patients to build an in vitro decidualization model through co-culture with medroxyprogesterone acetate (MPA) and 8-bromoadenosine cAMP (cAMP). SC79, a specific AKT activator in various physiological and pathological conditions, and shRNA-FKBP51 were used to examine the roles of AKT and FKBP51 in decidualization. The Western blot and RT-PCR results showed that FKBP51, insulin-like growth factor-binding protein 1 (IGFBP1) and prolactin (PRL) expression increased in ESCs treated with MPA+cAMP; meanwhile, the level of p-Ser473 AKT (p-S473 AKT) decreased and forkhead box protein O1 (FOXO1A) expression increased. Decidualization was inhibited by the AKT activator SC79 and the transfection of FKBP51-shRNA by affecting protein synthesis, cell morphology, cell growth and cell cycle. Furthermore, this inhibition was rescued by FKBP51-cDNA transfection. The results supported that FKBP51 promotes decidualization by reducing the Ser473 phosphorylation levels in AKT.


Introduction

Approximately 10%–15% of couples at their reproductive years have experienced infertility. A number of underlying causes of infertility can be partly overcome by in vitro fertilization and embryo transfer (IVF-ET), but the implantation rates remain unsatisfactory because embryos are transferred into a nonreceptive endometrium. Recently, defective decidualization has been highlighted as a major underlying cause of low receptivity (Wang & Dey 2006, Cha et al. 2012). In humans, decidualization is independent of pregnancy and is primarily a response to ovarian steroids and progesterone during the mid-luteal phase of the menstrual cycle. Adequate decidualization is needed for potential embryo implantation and is the precondition for the establishment and maintenance of pregnancy (Dey et al. 2004, Weimar et al. 2013). Decidualization promotes profound changes in cellular morphology, proliferation capability and gene expression and builds an extracellular matrix (ECM), which is the necessary structure for the blastocyst to invade, anchor itself tightly and absorb nutrients (Strowitzki et al. 2006). The proteins released by decidual cells, such as insulin-like growth factor-binding protein 1 (IGFBP1) and prolactin (PRL), are markers of decidualization levels (Bourdieu et al. 2016). In addition, decidualization can be modelled in vitro using primary endometrial stromal cells (ESCs) co-cultured with medroxyprogesterone acetate (MPA) and 8-bromoadenosine cAMP (8-Br-cAMP), facilitating studies investigating the underlying molecular mechanisms of decidualization (Bombail et al. 2010).

FKBP51 (also called FKBP5) is a 51-kDa protein that was first identified due to its ability to bind the immunosuppressant drugs FK506 and cyclosporine A. This high-molecular-weight immunophilin participates in diverse interactions and numerous functions, particularly those associated with steroid hormone responses (Storer et al. 2011). In certain cultured human cell lines, for example, prostate cancer cells, liver cancer cells (Hep G2) and breast carcinoma cells (T-47D), FKBP51 gene expression is rapidly upregulated by various steroid hormones, including progesterin and androgen but not oestrogen (Makkonen et al. 2009, Jaaskelainen et al. 2011). Furthermore, FKBP51 acts as a scaffolding protein...
for protein kinase B (AKT) and PH domain leucine-rich repeat protein phosphatase (PHLPP) and promotes the dephosphorylation of AKT at Ser473 (Pei et al. 2009). AKT is a serine/threonine protein kinase that regulates various cellular functions, including cell growth, the cell cycle, protein synthesis, glycogen synthesis and metabolism (Yoshino et al. 2003). Regulation of the AKT pathway is closely related to the decidualization process (Toyofuku et al. 2006). Yin and coworkers demonstrated that the downregulation of p-Ser473 AKT (p-S473 AKT) regulates the decidualization process by directly increasing the expression of forkhead box protein O1 (FOXO1A), a member of the forkhead box-O family and a nuclear transcription factor involved in cell apoptosis, cell differentiation and cell cycle arrest (Yin et al. 2012). In addition, FOXO1A can physically associate with the progesterone receptor to modulate the expression of decidual-specific genes (IGFBP1 and PRL) and inhibit the cell cycle and proliferation of differentiating ESCs (Takano et al. 2007). These previous studies suggest a possibility that FKBP51 regulates decidualization through the AKT pathway. Therefore, we hypothesized that FKBP51, a protein that participates in steroid hormone responses and the AKT pathway, might be involved in the regulation of decidualization in ESCs. The objective of the present study was to study the expression profile of FKBP51 in the decidualization process using a human tissue microarray and primary ESCs and to examine the potential mechanisms by which FKBP51 regulates decidualization.

Materials and methods

Immunohistochemistry (IHC) and tissue microarray (TMA)

A TMA (cat. no. UTN801) of the human endometrium was purchased from Xi’an Alena Biotechnology Ltd., Co. (Xi’an, China), and immunohistochemical staining of FKBP51 was performed by the company. Antigen retrieval was accomplished by heating the sections for 2 min in citrate buffer at a pH of 6.0. Endogenous peroxidase activity was blocked with 3% H2O2 for 30min. After subsequent blocking with 5% bovine serum albumin (BSA) for 30min, the sections were incubated overnight at 4°C with primary antibodies against FKBP51 (Abcam) diluted 1:400 in phosphate-buffered saline (PBS) and with PBS alone as a negative control. The sections were then incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies for 20min at 37°C. HRP activity was detected using 3,3-diaminobenzidine for 1 min. The slides were stained with haematoxylin for 5 min and then dehydrated and mounted using neutral balsam. The immunointensity and percentage of positive ESCs were measured using Image-Pro Plus software (Media Cybernetics Inc., MD, USA; Version 6.0.0.260). We applied a two-score system for immunointensity and immunopositivity as previously described to quantify FKBP51 immunoreactivity. The following scale was used for the immunointensity score: 0, negative; 1, weak; 2, moderate and 3, strong. The percentage of immunopositive cells was indicated by the following scores: 0, 1%; 1, 1–30%; 2, 30–60% and 3, more than 60%. The final scores were calculated by multiplying the immunointensity scores by the immunopositivity scores. We then defined low expression as a total score of 0–3, moderate expression as a total score of 3–6 and high expression as a total score of 6–9 (Xu et al. 2012, Yin et al. 2012). Three different regions in each section were measured in the same manner.

Tissue collection

Endometrial tissues were collected from 27 patients (age: 31.4 ± 4.2) undergoing hysteroscopic electroresection (HE) of endometrial polyps at the Centre for Reproductive Medicine, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China. All recruited patients had regular menstrual cycles (25–34 days) with confirmation of their menstrual cycle history, nutritional status (BMI: 22.2 ± 1.2) and normal levels of testosterone, oestradiol and progesterone (detected at the 2nd–4th day of the menstrual cycle). In addition, all 27 patients had not been treated with hormones for at least three months prior to surgery. All samples were obtained in the mid-follicular phase of the menstrual cycle. All participants provided written informed consent before HE. The use of human tissues was approved by the Institutional Review Board of Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.

Cell culture

Tissues were washed twice with PBS and minced into pieces of less than 1 mm3. After enzymatic digestion in PBS with 1% penicillin, 1% streptomycin and 0.1% collagenase I (GIBCO BRL, Grand Island, NY, USA) at 37°C for 1 h (shaking the tube every 15 min), the digested pieces were filtered through a 100-mesh sieve first, and then through a 40-μm nylon sieve (Corning) (Sugino et al. 2000, Matsuoka et al. 2010, Salker et al. 2011). The cells passed through the sieve into the filtrates were primarily ESCs, and the cells retained on the nylon sieve were primarily endometrial epithelial cells (EECs). We mixed the primary cells, which were isolated on the same date, into a mixture to ensure that a sufficient number of cells were isolated to allow normal growth. Samples from 20 patients were divided into 7 mixtures (Mix 1–7), and the samples from the remaining 7 patients were used for the preliminary experiments. ESCs and EECs were cultured in Phenol Red-free Dulbecco’s modified Eagle’s medium (DMEM/F12 (GIBCO) containing glutamine, antibiotics and 10% dextran-coated charcoal-stripped foetal bovine serum (CS-FBS) and maintained at 37°C and 5% CO2 in air. Because EECs are notoriously difficult to culture, we seeded the primary ECC cells directly into a 6-well plate and added stimulation at 70–80% confluence. The ESCs were directly seeded into bottles, grown to confluence and then were passaged for continuous cell culture. The percentage of stromal cells was verified by immunohistochemical staining on fixed cells using the stromal-specific antibody Vimentin (Abcam) and the epithelial-specific antibody CK8+18 (Abcam) at the third generation.

Cell treatment

To study decidualization, primary ESCs were co-cultured with either 1 μM MPA (Sigma) and 0.5 mM 8-Br-cAMP (Sigma)
FKBP51 regulates decidualization through AKT

Media were changed for 1:1000 4060S Cho ab79360 Abcam 1:250 et al. (2013). The impact of AKT on ESC was examined by flow cytometry. The overexpression and suppression rates were determined by performing Western blotting. FKBP51 cDNA was cloned into pcDNA3.1(+). In the rescue experiments, ESCs, grown to 60% confluence, were transfected using Lipofectamine 2000 (Invitrogen) with pcDNA3.1(+)/FKBP51 (3 μg in a 6-well plate) and empty pcDNA3.1(+). All transfections were performed in triplicate and repeated three times.

Transfection

The ESCs were transfected with cDNA-FKBP51 (GV230 vector) and shRNA-FKBP51 (GV248 vector) packaged into a lentivirus purchased from GeneChem BioTECH (Shanghai, China) to overexpress and knockdown FKBP51 expression. The cDNA sequences were commercially designed, and the sequences for the shRNA against FKBP51 have been described previously (Pei et al. 2009). After optimizing the experimental conditions, ESCs were seeded onto 24-well plates (30,000 cells/well) and were transfected using 5 μg/mL polybrene (GeneChem) with cDNA-FKBP51 or shRNA-FKBP51 using empty vectors as the respective controls (MOI: 50). The transfection efficiency was examined by flow cytometry. The overexpression and suppression rates were determined by performing Western blotting. FKBP51 cDNA was cloned into pcDNA3.1(+). In the rescue experiments, ESCs, grown to 60% confluence, were transfected using Lipofectamine 2000 (Invitrogen) with pcDNA3.1(+)/FKBP51 (3 μg in a 6-well plate) and empty pcDNA3.1(+). All transfections were performed in triplicate and repeated three times.

Western blot analysis

Total proteins were extracted by RIPA Lysis and Extraction Buffer (Thermo Fisher Scientific) supplemented with protease (Thermo Fisher Scientific) and phosphatase inhibitors (Roche). Protein concentrations were measured by the Micro BCA Protein Assay Kit (Thermo Fisher Scientific). Twenty micrograms of total protein were resolved on a 10% polyacrylamide gel and then transferred to a polyvinyl difluoride (PVDF) membrane. After blocking with 5% milk or 5% BSA for 1 h at room temperature, the PVDF membranes were incubated overnight at 4°C on a shaking table with antibodies against FKBP51, IGFBP1, PRL, vimentin, CK8+18, p-S473 AKT, p-T308 AKT, total AKT and FOXO1A (Abcam) and GAPDH (Santa Cruz). After washing with TBST, the membranes were incubated with HRP-conjugated goat anti-rabbit or anti-mouse secondary antibodies (Santa Cruz) for 1 h and then detected using the Immobilon Western Chemiluminescent HRP Substrate Kit (Merck Millipore) and the Amersham Imager 600 machine (GE Healthcare). The exposure time of the membrane was automatically detected by the machine. The grey values of the strips were analysed by ImageJ. GAPDH was used as an endogenous control for normalization. Applications of the antibodies are shown in Table 1. All Western blots were performed at least three times from independent experiments, and representative results are shown.

RNA isolation and real-time PCR

Total RNA was extracted using the Mini BEST Universal RNA Extraction Kit (Takara), then one microgram of total RNA was reverse-transcribed to cDNA using the PrimeScript RT Reagent Kit with gDNA Eraser (Takara). RT-PCR was performed using a Roche A700 sequence detection machine and SYBR GREEN (Takara) to quantify FKBP51, IGFBP1 and PRL mRNA levels. GAPDH was used as an internal control for normalization. The following specific primer pairs were designed using a software programme or as described in previous studies (Yang et al. 2012, Kuroda et al. 2013, Chen et al. 2014): FKBP51: 5'-AAAA AGG CCA AGG AGC ACA AC-3' (sense), 5'-TTG AGG AGG GCC CGA GTT C-3' (antisense); IGFBP1: 5'-CGA AGG CTC TCC ATG TCA CCA-3' (sense), 5'-TGT CTC TCT CGT TGC CTT GGC GTA AC-3' (antisense); PRL: 5'-AAG CTT TAG AGA TGT AGG AGC AAA C-3' (sense), 5'-TCA GGA TGA ACC TGG CTG ACT A-3' (antisense) and GAPDH: 5'-GGT ATC GTG GAA GGA GTC CTC-3' (sense), 5'-GTA GAG GCA GGG ATG ATG-3' (antisense).

Proliferation assays

Cell numbers were evaluated using a Cell Counting Kit-8 (CCK8) (DOJINDO, Kumamoto, Japan) to reflect cell growth. The cells were seeded onto 96-well plates at a density of 10,000 cells/well and cultured for 12 h to achieve complete adherence before stimulation. After treatment with SC79 and MPA + cAMP for 24, 48, 72 h, the media were changed to fresh media containing 10% CCK8 reagent and

### Table 1

<table>
<thead>
<tr>
<th>Name of antibody</th>
<th>Manufacturer</th>
<th>Catalogue</th>
<th>WB</th>
<th>IHC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-IGFBP-1 antibody</td>
<td>Abcam</td>
<td>ab10732</td>
<td>1:500</td>
<td></td>
</tr>
<tr>
<td>Anti-AKT1 (phospho S473) antibody</td>
<td>Abcam</td>
<td>ab81283</td>
<td>1:5000</td>
<td></td>
</tr>
<tr>
<td>Phospho-AKT (Ser473) Rabbit mAb</td>
<td>CST</td>
<td>4060S</td>
<td>1:2000</td>
<td></td>
</tr>
<tr>
<td>Anti-FOXO1A antibody</td>
<td>Abcam</td>
<td>ab52857</td>
<td>1:1000</td>
<td></td>
</tr>
<tr>
<td>Anti-Cytokeratin 8+18 antibody</td>
<td>Abcam</td>
<td>ab53280</td>
<td>1:50000</td>
<td>1:250</td>
</tr>
<tr>
<td>Anti-Vimentin antibody</td>
<td>Abcam</td>
<td>ab92547</td>
<td>1:1000</td>
<td>1:250</td>
</tr>
<tr>
<td>Anti-Prolactin antibody</td>
<td>Abcam</td>
<td>ab110642</td>
<td>1:1000</td>
<td></td>
</tr>
<tr>
<td>Anti-AKT1/2/3 antibody</td>
<td>Abcam</td>
<td>ab79360</td>
<td>1:1000</td>
<td></td>
</tr>
<tr>
<td>Anti-FKBP51 antibody</td>
<td>Abcam</td>
<td>ab46002</td>
<td>1:250</td>
<td>1:400</td>
</tr>
<tr>
<td>Anti-GAPDH antibody</td>
<td>Abcam</td>
<td>ab9485</td>
<td>1:5000</td>
<td></td>
</tr>
</tbody>
</table>
incubated for 1 h. The OD_{550}, which reflects the number of viable cells, was detected using a Thermo Scientific Multiskan GO (Thermo Fisher). All CCK8 tests were performed in triplicate and repeated three times.

**Flow cytometry**

ESCs were seeded into 75 mm² bottles. After treatments with MPA+cAMP for another 96 h, the ESCs were digested, collected and then fixed with pre-cooled 70% ethanol at 4°C overnight (Li et al. 2014). The fixed cells were washed twice with PBS and stained with BD PI/RNase Staining Buffer (BD Pharmingen, San Diego, CA, USA). The stained cells were detected using BD LSRFortessa to analyse the cell cycle distribution. All flow cytometry tests were repeated three times, and representative results are shown.

**Statistical analysis**

The results are presented as the mean±s.d. The data were statistically analysed using SPSS for Windows Statistics, version 20 (SPSS). The Mann–Whitney U test was used to analyse immunohistochemical staining scores. ANOVA and MANOVA were used to analyse the CCK8 results and the expression levels of Western results. Values of P<0.05 were considered statistically significant.

**Results**

**FKBP51 expression profile in the endometrium during in vivo decidualization**

To examine alterations in FKBP51 expression in endometrial cells during the human menstrual cycle, we purchased a TMA containing 80 endometria points derived from endometrial biopsies from females with normal cycles and no hormone treatment in the past three months. The TMA included 39 endometria points in the follicular phase and 41 endometria points in the luteal phase (17 points were excluded as uterine smooth muscle or endometrial carcinoma). As shown in Fig. 1A, various degrees of positive immunohistochemical staining for FKBP51 were observed in the epithelial glands and stromal cells. In ESCs, a total of 24 (61.5%) follicular phase samples and 3 (12.5%) luteal phase samples exhibited low FKBP51 expression. No follicular phase samples but 8 (33.3%) luteal phase samples showed high FKBP51 expression. Based on these results, FKBP51 expression levels in ESCs were significantly higher in the luteal phase than in the follicular phase (**P=0.000). However, there was no significant difference in FKBP51 expression between different stages of each phase in ESCs and EECs (Fig. 1B and Table 2).

**FKBP51 expression increased during ESC decidualization in vitro**

Immunohistochemical staining for Vimentin and CK8+18 revealed greater than 98% ESC purity at the third generation, and the ESC lysates did not contain CK8+18 (Fig. 1C and D). Primary ESC in vitro decidualization models had been well established through incubation with MPA+cAMP. Western blotting results (Fig. 1D) revealed remarkable upregulation of IGFBP1 after MPA+cAMP treatment for 4 days in ESCs, indicating the successful simulation of decidualization. ESCs under decidualization showed much stronger FKBP51 expression than the control cells. The expression levels of p-S473 AKT declined in decidualization, but the levels of p-T308 AKT remained the same. Furthermore, after treatment, ESCs exhibited obvious morphological changes from spindle-shaped fibroblast-like ESCs to more polygonal-shaped, enlarged secretory cells (Fig. 1E). EECs treated with MPA+cAMP did not change in cell shape but exhibited decreased FKBP51 and p-S473 AKT levels.

To further characterize the effects of decidualization on the expression of FKBP51 and other decidual-specific proteins, we analysed the proteins extracted from cultured ESCs in the presence of MPA+cAMP at days 0, 1, 2, 3, and 4. As shown in Fig. 1F, expression of the marker proteins IGFBP1 and PRL significantly increased with time, suggesting that ESCs treated with MPA+cAMP were undergoing effective decidualization during the 4 days. The expression of FKBP51 remarkably increased with progressing decidualization. In addition, we extracted total RNA from ESCs treated with MPA+cAMP at days 0, 2 and 4. The mRNA levels of FKBP51, IGFBP1 and PRL were detected using RT-PCR. As shown in Fig. 1G, MPA+cAMP strongly and synchronously increased FKBP51, IGFBP1 and PRL mRNA levels. FKBP51 mRNA levels in treated cells showed fold increases of 39.12±6.66 and 29.28±0.35 at 2 and 4 days, respectively.

To analyse the dose dependence of FKBP51 on MPA, ESCs were incubated with various doses of MPA (10⁻⁸, 10⁻⁶ and 10⁻⁴ M) in the presence of cAMP for 4 days. According to the Western blotting results, MPA+cAMP increased FKBP51 expression in a dose-dependent manner (Fig. 1H). To determine whether the progesterone receptor is necessary for the induction of FKBP51 protein expression during decidualization, ESCs were cultured for 4 days with MPA+cAMP as well as RU486, a progesterone-competitive antagonist with high affinity for PR. Treatment with RU486 blocked the induction of FKBP51 by MPA+cAMP (Fig. 1H).

**Reduced activation of the AKT pathway ensured ESC decidualization**

Previously, we observed levels of p-S473 AKT, p-T308 AKT and total AKT in ESCs undergoing MPA+cAMP treatment compared with control cells. To investigate the effects of the AKT pathway on ESC decidualization, we performed Western blotting on lysates extracted from cultured ESCs in the presence of MPA+cAMP at days 0, 1, 2, 3 and 4 to measure the proteins of the
FKBP51 regulates decidualization through AKT

Figure 1 FKBP51 expression during decidualization in vivo and in vitro. (A) Pictures of different expression levels of immunohistochemical staining of FKBP51 and negative controls on the tissue microarray UTN801. Original magnification, ×400. (B) Semi-quantification of FKBP51 expression in ESCs was significantly higher in the luteal phase than in the follicular phase (**P = 0.000). (C) Immunohistochemical staining of vimentin and CK8+18 in ESCs in the third generation showed that the ESC purity was more than 98%. Original magnification, ×200. (D) ESCs and EECs were treated with MPA + cAMP for 4 days. Protein levels were measured by performing a Western blot analysis (*P < 0.05; repeated in Mix 1, 2, 3). (E) The morphology of ESCs co-cultured with or without MPA + cAMP for 4 days is shown. Original magnification, ×200. (F) The expression of FKBP51, IGFBP-1 and PRL during MPA + cAMP-induced decidualization at days 0, 1, 2, 3 and 4 was analysed by Western blot analysis (*P < 0.05; repeated in Mix 2, 3, 4, 5). (G) Relative mRNA levels of FKBP51, IGFBP-1, and PRL on days 0, 2 and 4 were detected using real-time PCR (*P < 0.05; repeated in Mix 2, 3, 4, 5). (H) ESCs were cultured with 0.5 mM cAMP and various doses of MPA (10^{-8}, 10^{-6} and 10^{-4}M) with or without 1μM RU486 for 4 days. FKBP51 and IGFBP-1 levels were detected by performing a Western blot analysis (*P < 0.05; repeated in Mix 3, 4, 5).
AKT pathway. As shown in Fig. 2A, ESCs treated with MPA+cAMP exhibited lower p-S473 AKT levels than control ESCs. In addition, p-T308 AKT levels and total AKT expression levels did not show clear trends from day 0 to 4. Furthermore, we detected the expression of FOXO1A, an important protein in decidualization as well as a downstream protein of p-S473 AKT. Expression of FOXO1A gradually increased from day 0 to day 4. These data suggested that the AKT pathway may be a predominant signalling pathway to ensure adequate decidualization.

To confirm the role of the AKT pathway in the decidualization response, the AKT activator SC79 was used in co-culture with ESCs in the presence or absence of MPA+cAMP. As expected, SC79 increased p-S473 AKT levels, whereas total AKT levels remained the same (Fig. 2B). Treatment with various doses of SC79 (1, 4 and 8 μg/mL) and MPA+cAMP decreased IGFBP1 expression in a dose-dependent manner; the expression levels of FOXO1A were also simultaneously decreased, suggesting that decreased activation of the AKT pathway is required for ESC decidualization (Fig. 2C).

Effects of FKBP5 expression on decidualization

We further explored the consequences of disrupted FKBP5 expression during decidualization. First, we transfected ESCs with lentiviruses containing an empty vector as a negative control (FKBP51-NC), shRNA-FKBP51 (FKBP51-KD) to knockdown FKBP51 and cDNA-FKBP51 (FKBP51-OE) to overexpress FKBP51. Flow cytometry analysis showed that the transfection efficiency of the negative control lentivirus was 81.5% ± 4.2, and the transfection rates of the knockdown lentiviral vector and overexpression vectors were 91.5% ± 3.4 and 98.7% ± 1.6, respectively (Fig. 3A). Second, we detected the proteins affected by FKBP51 knockdown and overexpression in transfected cells. As shown in Fig. 3B, in FKBP51-KD ESCs, FKBP51 expression was suppressed by 52.90 ± 9.23%, and p-S473 AKT levels increased, which was accompanied by the downregulated expression of FOXO1A. In FKBP51-OE ESCs, the effects of FKBP51 overexpression were remarkable, leading to decreased p-S473 AKT levels and a significant increase in FOXO1A.

By performing Western blot analysis on the lysates of FKBP51-NC and FKBP51-KD ESCs treated with MPA+cAMP for 0, 2 and 4 days, we detected the impact of FKBP51 knockdown on ESCs during decidualization. Figure 4A shows that FKBP51 expression in FKBP51-NC ESCs exhibited an increasing trend during decidualization, but this trend was strongly inhibited in FKBP51-KD ESCs. The upregulated expression of the decidualization markers IGFBP1 and PRL in response to MPA+cAMP was also reduced by FKBP51 suppression. In addition, p-S473 AKT levels increased and FOXO1A expression decreased. The typical morphological changes accompanying decidualization disappeared in FKBP51-KD ESCs (Fig. 4B). Moreover, a CCK8 kit was employed to construct proliferation curves for FKBP51-NC and FKBP51-KD ESCs in the presence or absence of MPA+cAMP. As shown in Fig. 4C, the proliferation of ESCs transfected with a negative control virus was remarkably suppressed after treatment with MPA+cAMP (**P < 0.01), but in FKBP51-KD ESCs, the proliferation of ESCs did not differ significantly with or without MPA+cAMP treatment (except at 72 h). Furthermore, the transformation of ESCs into decidual cells requires a cell cycle change. According to the flow cytometry results (Fig. 4D), FKBP51 knockdown reduced cell cycle arrest at the G1/S phase (99.55%–86.08%), which is required for ESC decidualization and the inhibition of stromal cell differentiation. All these results suggested that the in vitro decidualization induced by MPA+cAMP was inhibited via FKBP51 suppression in FKBP51-KD ESCs.
FKBP51 regulates decidualization through AKT

Fig. 2 Expression and regulation of the AKT pathway during decidualization. (A) ESCs were treated with MPA+cAMP for 0, 1, 2, 3 and 4 days. The phosphorylation levels at the Ser473 and Thr308 sites in AKT and the level of FOXO1A were detected by performing a Western blot analysis (*\(P<0.05\); repeated in Mix 2, 3, 4, 5). (B) We collected the proteins of ESCs treated with different doses of SC79 (1, 4 and 8 \(\mu\)g/mL) for 24 h and performed Western blot analysis to detect the level of p-S473 AKT (*\(P<0.05\); repeated in Mix 3, 4, 5). (C) To confirm the effects of AKT on decidualization, we treated ESCs with different doses of SC79 (1, 4 and 8 \(\mu\)g/mL) and/or MPA+cAMP for 4 days and collected total protein. P-S473 AKT levels and the expression of total AKT, FOXO1A, IGFBP-1 and PRL were detected by Western blot analysis (*\(P<0.05\); repeated in Mix 3, 4, 5).

Discussion

To our knowledge, the present study is the first to implicate FKBP51 as an indispensable element in supporting the decidualization of ESCs. Decidualization involves a complicated and highly interactive set of interacting signalling pathways that regulate the effects of sex steroid communication via transcription factors and cytokines, resulting in controlled cell growth, cell cycle changes and stroma cell decidual differentiation in the endometrium (Tan et al. 2002, Curry & Osteen 2003). Decidualized ESCs play a role in ensuring the uterine receptivity to implantation, while defective decidualization contributes to infertility (Das 2009).

Our results first demonstrate that the expression of FKBP51 is altered during the decidualization of ESCs both in vivo and in vitro. The significant difference in FKBP51 expression observed between the follicular and luteal endometria by the TMA shows that FKBP51 expression in Fig. 5B, SC79 inhibited IGFBP1, PRL and FOXO1A upregulation induced by MPA+cAMP, but FKBP51 overexpression recovered the expression of these decidualization marker proteins. A CCK8 test performed with FKBP51-NC and FKBP51-OE ESCs treated with PBS as a control or MPA+cAMP for 4 days, with or without 24 h of pretreatment with SC79 (4 \(\mu\)g/mL), also indicated that SC79 blocked the decreased proliferation induced by MPA+cAMP, but these inhibition effects were rescued by FKBP51 overexpression (Fig. 5C).
is upregulated in vivo during human decidualization. As previously described, decidualization is mainly induced by progesterone during the mid-luteal phase in humans, regardless of the presence or absence of an embryo; decidualization in humans is clearly different than that, which occurs in mice. Mouse decidualization is initiated through both steroid hormones and the presence of an embryo or a surrogate stimulus occurring near the location of embryo implantation (Yang et al. 2006). Thus, we believe that our initial tissue array results suggest that FKBP51 have more functions in humans than in mice, although studies using female FKBP51 genetically modified mice showed that these mice were fertile and normal (Stechschulte et al. 2016). Our in vitro data provide evidence that FKBP51 expression is increased in a decidualization model. These results agree with the finding that FKBP51 can be strongly upregulated by androgen, glucocorticoid, mineralocorticoid and progesterone signalling (Jaaskelainen et al. 2011). In previous studies investigating the functions of ESCs, FKBP51 mRNA sharply increased after treatment with MPA, as confirmed by a whole genome microarray analysis (Guzeloglu Kayisli et al. 2015). Studies in T-47D and HepG2 cells indicate FKBP51 gene expression is directly regulated by progesterone (Hubler et al. 2003). In the present study, progesterone induced a time- and dose-dependent upregulation of FKBP51 expression, which could be blocked by RU486. Previous studies showed that FKBP51 plays a role as one of the components that regulate both progesterone receptor and glucocorticoid receptor (GR) activity (Sinars et al. 2003, Caldwell et al. 2010). RU486 is the most widely used PR antagonist, has a high affinity for PR, competes with progesterone (Wardell et al. 2010) and is also an antagonist of the GR (Rearte et al. 2010). The MPA-induced increase can be blocked by the PR antagonist RU486, which suggests that MPA may activate FKBP51 expression via a steroid hormone receptor. Expression of FKBP51 appears important for adequate decidualization because transfection with FKBP51 siRNA markedly reduced the induction of decidualization at both the protein and phenotype levels, as indicated by cell images and reduced expression of IGFBP1 and PRL. However, FKBP52, another large immunophilin FKBP, has a similar structure as FKBP51 and also plays a role in decidualization. Both proteins are Hsp90 co-chaperones that modify steroid hormone receptor activity but have diverse regulation in steroid hormone receptor signalling (Storer et al. 2011). FKBP52 governs normal PR function in the mouse uterus (Tranguch et al. 2006). Transgenic FKBP52-null mice have complete implantation failure, although ovulations are normal (Tranguch et al. 2007). Women with endometriosis have low levels of FKBP52 expression, leading to infertility mainly due to impaired decidualization through homeobox A10 (HOXA10)-regulated FKBP52 expression (Yang et al. 2012). In the present study, the potential roles of FKBP51 and FKBP52 in the human menstrual cycle were detected by immunohistochemical staining of the TMA, but we did not observe a significant difference in the expression of FKBP52 between the follicular phase and the luteal phase.
FKBP51 regulates decidualization through AKT

The results suggest that stable FKBP52 expression is required for decidualization in a normal menstrual cycle, and the lack of FKBP52 in a disease state will lead to impaired decidualization.

Deficient AKT levels disrupt the intracellular balance between survival and death, affecting numerous biochemical processes. In type 1 endometrial cancer, the cell-autonomous hyperactivation of AKT is essential for triggering endometrial carcinoma in epithelia (Memarzadeh et al. 2010). In endometriosis, the AKT pathway is hyperactivated, contributing to the pathogenesis of progesterone resistance and the attenuation of decidualization through its downstream target (Cinar et al. 2009, Velarde et al. 2009).
Figure 5 Rescue effects of FKBP51 overexpression. (A) FKBP51-NC and FKBP51-KD ESCs were seeded onto six-well plates and transfected with a pcDNA3.1(+) FKBP51 plasmid or empty pcDNA3.1(+) for 12 h. After incubation for an additional 48 h, the cells were treated with PBS as a control or MPA + cAMP for 4 days. Protein expression levels were detected by performing Western blot analysis (*P < 0.05; repeated in Mix 5, 6, 7). (B and C) FKBP51-NC and FKBP51-OE ESCs were seeded onto six-well plates and treated with PBS as a control or MPA + cAMP for 4 days, with or without 24-h pretreatment with SC79 (4 μg/mL). Proteins were analysed by Western blotting, and changes in proliferation were detected by performing a CCK8 assay (*P < 0.01, **P < 0.05; repeated in Mix 5, 6, 7). (D) The signalling pathway underlying FKBP51 regulation of decidualization is demonstrated in the present study.
addition, the activation of decidualization-specific genes requires not only PR but also FOXO1A, a member of the forkhead transcription factor subfamily, which is one of the direct targets of p-S473 AKT (Takano et al. 2007). FOXO1A plays a significant role in decidualization, including interacting with progesterone receptors to initiate decidualization and promote IGFBP1, PRL and decorin (DCN) expression (Kim et al. 2005, Buzzio et al. 2006, Labied et al. 2006). The modulation of the AKT pathway is of critical importance to the establishment of decidualization in vivo and in vitro (Hirotah et al. 2010, Mori et al. 2011). Total AKT protein is always stable in any stage of the menstrual cycle, but the levels of p-S473 AKT show decrease in mid-secretory endometria (Toyofuku et al. 2006). Primary ESCs undergoing decidualization through progesterone supplementation exhibit reduced levels of p-S473 AKT (Yoshino et al. 2003, Yin et al. 2012). The observed significant decrease in p-S473 AKT levels in an in vitro decidualization model, as well as the attenuation of decidual marker expression in ESCs by SC79 (a synthetic compound that suppresses PHAKT-GFP plasma membrane translocation but enhances AKT phosphorylation and activation in the cytosol), in the present study, verified the correlation of reduced p-S473 AKT with ESC decidualization.

The underlying mechanism and factors responsible for the decrease of p-S473 AKT during decidualization in ESCs remains unknown. The decrease in AKT activity in decidualization is isoform specific and site specific and does not involve ubiquitin-proteasome degradation (Fabi et al. 2017). Progesterone, which regulates the activation of AKT in many cell types and induces the decidualization of ESCs, may be involved. Our current study demonstrated that progesterone induced the expression of FKBP51 in ESCs. FKBP51 has recently been identified as a negative factor that enhances the phosphatase activity of PHLPP towards AKT (Gao et al. 2005). Overexpression or downregulation of FKBP51 leads to specific interactions between PHLPP isoforms and their corresponding AKT isoforms, suggesting that FKBP51 facilitates isoform-specific and site-specific regulation of AKT (Wang 2011). We performed two rescue experiments to assess the relationship between these crucial factors. The inhibition of decidualization marker proteins using FKBP51 shRNA was rescued by pcDNA3.1(+)/FKBP51, and the inhibition of decidualization proteins and the abnormal changes of proliferation ability induced by SC79 were rescued by FKBP51 overexpression. These results suggested that in the process of in vitro decidualization, the phosphorylation levels of p-S473 AKT were regulated by the FKBP51 expression induced by progesterone. As shown in Fig. 5D, the FKBP51 upregulation induced by MPA can specifically increase the dephosphorylation of the Ser473 site in AKT and therefore alter downstream factors that affect decidualization.

Unfortunately, the sample size and methods of our study have their limits, weakening our conclusions. For now, we cannot explain the distinct roles of FKBP51 in mouse and human decidualization. Besides, we only detected the functions of FKBP51 in regulating the p-S473 AKT pathway in decidualization. There are still many pathways and factors having potential relationships with FKBP51 and decidualization that should be studied.

In summary, our findings strongly suggest that FKBP51 is a new indispensable element of ESC decidualization. Because FKBP51 expression is markedly induced in primary ESC during decidualization and the presence of FKBP51 is needed for adequate decidualization. In addition, the regulations of FKBP51 on p-S473 AKT pathway could explain the decrease of p-S473 AKT levels in in vitro decidualization, which were observed by numerous researchers. This study provides a foundation for more in-depth and detailed research to be performed in the future.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
This study was funded by The National Key Research and Development Program of China (2017YFSF080004).

Author contribution statement
Prof. Yueran Zhao designed and supervised the study. Muyun Wei designed and performed most of the tests, analysed the data and wrote the manuscript. Lei Yan provided help collecting the patient tissues. Ying Gao, Bingru Lu, Yulian Jiao, Xiaowen Liu, Bin Cui, Shengnan Hu, Linying Sun and Jing Dong performed parts of the experiments. All authors reviewed the paper and approved the final manuscript.

References


Clinical Immunology 125 879-88. e8. (https://doi.org/10.1016/j.clinim.2010.01.038)

FKBP51 regulates decidualization through AKT


Received 14 October 2017
First decision 13 November 2017
Revised manuscript received 13 January 2018
Accepted 22 January 2018